Vaccine and Gene, Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, 505 NW 185th Avenue, 97006, Beaverton, OR, USA.
Curr Top Microbiol Immunol. 2022;435:107-139. doi: 10.1007/82_2020_195.
Chikungunya virus (CHIKV) infection in humans is rarely fatal but is often associated with chronic joint and muscle pain. Chronic CHIKV disease is highly debilitating and is associated with viral persistence. To date, there are no approved vaccines or therapeutics to prevent or treat CHIKV infections once they are established. Current palliative treatments aim to reduce joint inflammation and pain associated with acute and chronic CHIKV disease. Development of novel therapeutics that reduces viral loads should positively impact virus inflammatory disease and improve patient outcomes following CHIKV infection. Therapies that target multiple aspects of CHIKV replication cycle should be developed since the virus is capable of rapidly mutating around any single therapeutic. This review summarizes the current status of small molecule inhibitor development against CHIKV.
基孔肯雅病毒（CHIKV）感染在人类中很少致命，但常与慢性关节和肌肉疼痛有关。慢性 CHIKV 病高度使人虚弱，并与病毒持续存在有关。迄今为止，尚无批准的疫苗或疗法可预防或治疗已建立的 CHIKV 感染。目前的姑息治疗旨在减轻与急性和慢性 CHIKV 疾病相关的关节炎症和疼痛。开发可降低病毒载量的新型疗法应可积极影响病毒炎症性疾病，并改善 CHIKV 感染后的患者结局。由于病毒能够迅速围绕任何单一治疗方法发生突变，因此应开发针对 CHIKV 复制周期多个方面的治疗方法。本综述总结了针对 CHIKV 的小分子抑制剂开发的现状。
Zotero 插件